Chris Froome failed urine test at Vuelta

Salbutamol, which doesn't require a therapeutic use exemption (TUE), is taken to treat asthma which Froome suffers from.

The UCI said analysis of the B sample had confirmed the results of the rider's A sample and proceedings were being conducted in line with its anti-doping rules.

"As always, I took the greatest care to ensure that I did not use more than the permissible dose", he said.

The Union Cycliste Internationale (UCI) confirms that British rider Christopher Froome was notified of an Adverse Analytical Finding (AAF) of Salbutamol in excess of 1000ng/ml (*) in a sample collected during the Vuelta a España on 7 September 2017.

According to Sky Team, Froome was tested after every stage through this period and had declared the use of the medication as part of the process.

"I have the utmost confidence that Chris followed the medical guidance in managing his asthma symptoms, staying within the permissible dose for Salbutamol".

After successfully defending his Tour de France title in July, Froome went on to win the Spanish Vuelta for the first time.

Team Sky have said that Froome experienced "acute asthma symptoms" in the final week of the Vuelta and on the advice of the team doctor he increased his dosage of Salbutamol, which they say was "still within the permissible doses".

"I take my leadership position in my sport very seriously".

The statement added that dosages of Salbutamol could sometimes result in higher urinary concentrations and that a wide range of factors would affect the concentrations, including the medication's interaction with food and other medications.

The UCI, who disclosed the information to Froome on Sep.

The UCI has asked Froome to provide more information but has not suspended him. "We're committed to establishing the facts and understanding exactly what happened on this occasion", Brailsford said in the team release.

In a statement from the team, Froome explained that his symptoms worsened and he sought medical advice from the team doctor.

The test will raise new questions about British cycling following the scandal surrounding the only previous British Tour de France victor, Bradley Wiggins, over his use of so-called therapeutic use exemptions (TUEs). "Of course, we will do whatever we can to help address these questions".

Related Articles